Thermo Fisher Scientific Inc.
TMONYSE
$667.55
Last price · USD
- Market cap
- $251.7B
- P/E
- 37.6x
- EV / EBITDA
- 24.5x
- P/S
- 5.6x
- FCF yield
- 2.5%
- Div. yield
- 0.25%
Multiples use last price and FY2025 annual figures. Market cap estimated from diluted shares.
Thermo Fisher Scientific Inc. key metrics & ratios
Annual · USD millions except per-share data · 36 lines
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | CAGR | |
|---|---|---|---|---|---|---|---|
| Growth (year over year) | |||||||
| Revenue growth | 3.9% | 0.1% | -4.6% | 14.5% | — | — | |
| Operating income growth | 5.8% | 2.9% | -12.7% | -17.4% | — | — | |
| Net income growth | 6.3% | 5.7% | -13.7% | -10.0% | — | — | |
| EPS (diluted) growth | 7.3% | 7.0% | -12.4% | -9.4% | — | — | |
| Free cash flow growth | -13.4% | 4.9% | 0.2% | -1.6% | — | — | |
| Margins | |||||||
| Gross margin | 40.9% | 41.3% | 40.1% | 42.3% | 50.1% | — | |
| Operating margin | 18.2% | 17.9% | 17.4% | 19.0% | 26.3% | — | |
| EBITDA margin | 25.7% | 27.5% | 26.1% | 26.6% | 30.5% | — | |
| Net margin | 15.1% | 14.8% | 14.0% | 15.5% | 19.7% | — | |
| FCF margin | 14.1% | 16.9% | 16.2% | 15.4% | 17.9% | — | |
| Returns on capital | |||||||
| Return on equity | 12.6% | 12.8% | 12.8% | 15.8% | 18.9% | — | |
| Return on assets | 6.1% | 6.5% | 6.1% | 7.2% | 8.1% | — | |
| Return on invested capital | 9.0% | 8.9% | 9.5% | 10.8% | 12.4% | — | |
| Leverage & liquidity | |||||||
| Debt / equity | 0.74x | 0.66x | 0.78x | 0.82x | 0.89x | — | |
| Net debt / EBITDA | 2.58x | 2.44x | 2.53x | 2.31x | 2.66x | — | |
| Current ratio | 1.89x | 1.66x | 1.75x | 1.48x | 1.50x | — | |
| Interest coverage | 5.71x | 4.63x | 4.99x | 11.74x | 19.25x | — | |
| Profitability & operating | |||||||
| EBIT | 8,686 | 8,692 | 7,789 | 8,561 | 9,377 | -1.9% | |
| EBITDA | 11,466 | 11,800 | 11,195 | 11,942 | 11,969 | -1.1% | |
| Operating income | 8,109 | 7,662 | 7,446 | 8,525 | 10,318 | -5.8% | |
| Income before tax | 7,267 | 6,995 | 6,239 | 7,663 | 8,837 | -4.8% | |
| Net income | 6,737 | 6,335 | 5,995 | 6,950 | 7,725 | -3.4% | |
| Earnings per share | |||||||
| EPS (basic) | $17.77 | $16.58 | $15.53 | $17.73 | $19.61 | -2.4% | |
| EPS (diluted) | $17.74 | $16.53 | $15.45 | $17.64 | $19.46 | -2.3% | |
| Share count (millions) | |||||||
| Weighted avg shares outstanding | 376 | 382 | 386 | 392 | 394 | -1.2% | |
| Weighted avg shares outstanding (diluted) | 377 | 383 | 388 | 394 | 397 | -1.3% | |
| Balance sheet highlights | |||||||
| Net debt | 29,533 | 28,766 | 28,341 | 27,549 | 31,862 | -1.9% | |
| Total debt | 39,385 | 32,775 | 36,424 | 36,073 | 36,339 | +2.0% | |
| Total investments | 253 | 2,121 | 59 | 155 | 73 | +36.4% | |
| Total stockholders' equity | 53,407 | 49,584 | 46,735 | 43,978 | 40,793 | +7.0% | |
| Total assets | 110,343 | 97,321 | 98,726 | 97,154 | 95,123 | +3.8% | |
| Cash flow highlights | |||||||
| Free cash flow | 6,293 | 7,267 | 6,927 | 6,911 | 7,020 | -2.7% | |
| Operating cash flow | 7,818 | 8,667 | 8,406 | 9,154 | 9,543 | -4.9% | |
| Capital expenditure | (1,525) | (1,400) | (1,479) | (2,243) | (2,523) | — | |
| Net cash from operating activities | 7,818 | 8,667 | 8,406 | 9,154 | 9,543 | -4.9% | |
| Additional fields | |||||||
| Accrued Expenses | 5,324 | 1,988 | 1,596 | 2,095 | 2,427 | +21.7% | |